Undisclosed TBK1 inhibitor / Exo Therap - LARVOL DELTA

Exo Therapeutics Presents Data on Novel Exosite Inhibitors of TBK1 (EXO-TBKi) Shown to Disrupt Pathological STING-mediated TBK1 Activation at American College of Rheumatology’s Convergence (ACR) (Businesswire) - "Exo Therapeutics, Inc...today presented a late-breaking poster on its preclinical program targeting the TBK1/STING interaction of the cGAS-STING pathway at the American College of Rheumatology’s Convergence Conference (ACR) in Washington, D.C....Data presented show that EXO-TBKis, novel TBK1 inhibitors that selectively and potently inhibit the TBK1/STING pathway, demonstrated efficacy in multiple cellular and mouse models as well as patient-derived samples. These findings support the company’s nomination of a lead development candidate for the treatment of autoimmune diseases such as Systemic and Cutaneous Lupus (SLE and CLE), Systemic Sclerosis (scleroderma, SSc) and Sjögren’s Syndrome."

Preclinical • Immunology • Lupus • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis

Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases (ACR Convergence 2024) - "We discovered novel TBK1 inhibitors that selectively and potently inhibit the TBK1-STING pathway via specific inhibition of interferon and NF-κB while sparing the non-disease relevant functions of the kinase, a first-in-class mechanism that offers highest therapeutic benefit. We demonstrate efficacy across preclinical models and are progressing towards developmental candidate nomination for clinical opportunity in auto-immune diseases such as lupus, SSc and Sjogren's."

Late-breaking abstract • Cutaneous Lupus Erythematosus • Fibrosis • Immunology • Inflammation • Inflammatory Arthritis • Interferonopathies • Lupus • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis • CXCL10 • CXCL9 • GLI2 • IFIT1 • IFNB1 • STING • TREX1

Exo Therapeutics Presents Key Data at FOCIS 2024 Demonstrating the Efficacy of Potent and Selective Exosite-targeted TBK1/STING Inhibitor in Multiple Preclinical Models (Businesswire) - "Exo Therapeutics...presented a poster and oral presentation on its preclinical program targeting TBK1/STING interaction of the cGAS-STING pathway at the 24th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2024)...Data presented in both the poster and oral presentation show that the company has identified potent, selective exosite-targeted TBK1/STING inhibitors, demonstrated efficacy across preclinical models and optimized properties towards development candidate nomination...'There is a great need to define the role of the TBK1/STING pathway in Systemic Lupus Erythematosus (SLE) and other autoimmune diseases.'....The presentations detailed Exo’s novel TBK1 exosite inhibitors that disrupt recruitment by STING for downstream activation of type-1 interferon and NF-κB responses."

Preclinical • Immunology • Systemic Lupus Erythematosus

A Novel Exosite Inhibitor that Selectively Reprograms TBK1-STING Pathway for Autoimmune Diseases (FOCIS 2024) - "Similarly, upon activation of pathway, EXO-TBKi reduces cytokine production in disease relevant skin inflammatory models, fibroblasts and keratinocytes. In summary, we have identified potent, selective EXO-TBK1 inhibitors, demonstrated efficacy across pre-clinical models and optimized properties towards developmental candidate nomination."

Late-breaking abstract • Immunology • Inflammatory Arthritis • Lupus • Scleroderma • Systemic Sclerosis • CXCL10 • CXCL9 • GLI2 • IFIT1 • IFNB1

A Novel Exosite Inhibitor that Selectively Reprograms TBK1-STING Pathway for Autoimmune Diseases (FOCIS 2024) - "Similarly, upon activation of pathway, EXO-TBKi reduces cytokine production in disease relevant skin inflammatory models, fibroblasts and keratinocytes. In summary, we have identified potent, selective EXO-TBK1 inhibitors, demonstrated efficacy across pre-clinical models and optimized properties towards developmental candidate nomination."

Immunology • Inflammatory Arthritis • Lupus • Scleroderma • Systemic Sclerosis • CXCL10 • CXCL9 • GLI2 • IFIT1 • IFNB1

Exo Announces Lead Program, Targeting TANK Binding Kinase 1 (TBK1), for the Treatment of Autoimmune Diseases (Businesswire) - "Exo Therapeutics...today announced its lead program directed against TBK1, and the appointment of Alexandra Joseph, PhD, as Executive Vice President of Biology. Dr Joseph will be responsible for leading biology, translational and pre-clinical work for Exo’s programs....'Her experience and leadership, with particular expertise in autoimmune diseases, will be especially important as we approach identification of a development candidate for our lead program, an exosite-targeted compound that selectively reprograms the activity of TBK1 in the STING pathway that drives pathogenic signaling in diseases such as Systemic Lupus Erythematosus (SLE), Aicardi-Goutières Syndrome (AGS) and others.'...Exo intends to declare a development candidate in their lead program later this year and enter the clinic within the next two years."

Preclinical • Aicardi Goutieres Syndrome • Immunology • Interferonopathies • Systemic Lupus Erythematosus